Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05995353 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
A Phase 3 study of Crohn's Disease, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT05995353 is a Phase 3 study of Crohn's Disease that is actively recruiting participants, run by AbbVie. The registered enrollment target is 110 participants, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT05995353, a Phase 3 study of Crohn's Disease, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to \< 18 years old who have had intolerance or inadequate response to other therapies. Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 110 pediatric participants with CD will be enrolled at around 100 sites worldwide. Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side
Conditions Studied
Interventions
- DRUG Risankizumab
Study Locations (20)
Other
- Hospital Universite Enfants Reine Fabiola /ID# 255112 - Brussels
- UMHAT Sveti Georgi /ID# 255386 - Plovdiv
- Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 255384 - Sofia
- UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 256358 - Varna
Brussels Capital
- Cliniques Universitaires UCL Saint-Luc /ID# 255108 - Brussels
- Universitair Ziekenhuis Brussel /ID# 255109 - Jette
Arizona
- Phoenix Children's Hospital /ID# 255766 - Phoenix
Arkansas
- Arkansas Children's Hospital /ID# 255762 - Little Rock
California
- UCSF Benioff Children's Hospital - Oakland /ID# 258327 - Oakland
Colorado
- Children's Hospital Colorado - Aurora /ID# 255764 - Aurora
Florida
- Arnold Palmer Hospital for Children Center Digestive Health & Nutrition - Orland /ID# 255437 - Orlando
Indiana
- Indiana University Health Riley Hospital for Children /ID# 256454 - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2023-12-11 |
| Est. Completion | 2029-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05995353
The ClinicalTrials.gov registry entry for NCT05995353 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (95% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Risankizumab is the first listed.
NCT05995353 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, Brussels Capital, Arizona.
Frequently Asked Questions
What is clinical trial NCT05995353 about?
NCT05995353 is a clinical study titled "A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease". Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD...
What is the current status of trial NCT05995353?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2023-12-11. Estimated completion is 2029-04.
What conditions does trial NCT05995353 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT05995353?
The interventions under investigation include: Risankizumab (DRUG).
Who is sponsoring clinical trial NCT05995353?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05995353 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.